Status and phase
Conditions
Treatments
About
This research study is evaluating a drug called enzalutamide in metastatic castration resistant prostate cancer. Enzalutamide is already FDA approved for metastatic castration resistant prostate cancer after treatment with chemotherapy.
The purpose of this study is to analyze features of tumor specimens sampled prior to therapy and at disease progression to determine why patients respond or stop responding to treatment with Enzalutamide.
Prior chemotherapy is not a requirement of this trial.
Full description
After the screening procedures confirm that the patient is able to participate in the study,
On Day 1 of each cycle (+/- 4 days), the following procedures will be performed in clinic:
Every 12 weeks (+/-1 week) the following procedures will be performed in clinic:
End of Study Visit in clinic:
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Clinically significant heart disease as evidenced by:
Primary purpose
Allocation
Interventional model
Masking
67 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal